Evidence map›Paper›PMID 15980348›Full record

ArticleAntimicrobial agents and chemotherapy2005

Novel approach to mapping of resistance mutations in whole genomes by using restriction enzyme modulation of transformation efficiency.

Claude G Lerner, Stephan J Kakavas, Christian Wagner, Richard T Chang, Philip J Merta, Xiaoan Ruan, Randy E Metzger, Bruce A Beutel

Open access · greenAbstract readEvaluation Study
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Clicking on trans-translation drug targets.Frontiers in microbiology · 2015
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Claude G LernerGlobal Pharmaceutical Research Division, Abbott Laboratories, R4CC, AP10-1, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA. claude.lerner@abbott.com
Stephan J Kakavas
Christian Wagner
Richard T Chang
Philip J Merta
Xiaoan Ruan
Randy E Metzger
Bruce A Beutel
Abbott Fund · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Restriction enzyme modulation of transformation efficiencies (REMOTE) is a method that makes use of genome restriction maps and experimentally observed differences in transformation efficiencies of genomic DNA restriction digests to discover the location of mutations in genomes. The frequency with which digested genomic DNA from a resistant strain transforms a susceptible strain to resistance is primarily determined by the size of the fragment containing the resistance mutation and the distance of the mutation to the end of the fragment. The positions of restriction enzyme cleavage sites immediately flanking the resistance mutation define these parameters. The mapping procedure involves a process of elimination in which digests that transform with high frequency indicate that the restriction enzyme cleavage sites are relatively far away from the mutation, while digests that transform with low frequency indicate that the sites are close to the mutation. The transformation data are compared computationally to the genome restriction map to identify the regions that best fit the data. Transformations with PCR amplicons encompassing candidate regions identify the resistance locus and enable identification of the mutation. REMOTE was developed using Haemophilus influenzae strains with mutations in gyrA, gyrB, and rpsE that confer resistance to ciprofloxacin, novobiocin, and spectinomycin, respectively. We applied REMOTE to identify mutations that confer resistance to two novel antibacterial compounds. The resistance mutations were found in genes that can decrease the intracellular concentration of compounds: acrB, which encodes a subunit of the AcrAB-TolC efflux pump; and fadL, which encodes a long-chain fatty acid transporter.

Indexed as

Genome, BacterialAnti-Bacterial AgentsBacterial Outer Membrane ProteinsBacterial ProteinsCarrier ProteinsDNA Restriction EnzymesDrug Resistance, BacterialEscherichia coli ProteinsFatty Acid Transport ProteinsHaemophilus influenzaeMembrane Transport ProteinsMicrobial Sensitivity TestsMutationRestriction MappingTransformation, BacterialAcrB protein, Salmonella entericaAnti-Bacterial AgentsBacterial Outer Membrane ProteinsBacterial ProteinsCarrier ProteinsDNA Restriction EnzymesEscherichia coli ProteinsfadL protein, E coliFatty Acid Transport ProteinsMembrane Transport Proteins

Identifiers

PMID15980348
PMCPMC1168657
OpenAlexW1991678645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.